SynAct Pharma: Start of Phase II in Arboviral Infections - Redeye
Bildkälla: Stockfoto

SynAct Pharma: Start of Phase II in Arboviral Infections - Redeye

Redeye is optimistic about the start of a well-sized phase II study in patients with Dengue fever and provides an updated base case.

Redeye is optimistic about the start of a well-sized phase II study in patients with Dengue fever and provides an updated base case.
Börsvärldens nyhetsbrev
ANNONSER